Search

Your search keyword '"Valentín García-Gutierrez"' showing total 4 results
Start Over Author "Valentín García-Gutierrez" Journal hemasphere
4 results on '"Valentín García-Gutierrez"'

1. Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

Author

Adrián Mosquera‐Orgueira, Eduardo Arellano‐Rodrigo, Marta Garrote, Iván Martín, Manuel Pérez‐Encinas, María‐Teresa Gómez‐Casares, Alberto Hernández‐Sánchez, Francisca Ferrer‐Marín, Elvira Mora, Patricia Velez, Rosa Ayala, Anna Angona, Natalia de las Heras, Elena Magro, Carlos Pérez‐Míguez, Davide Crucitti, María‐Isabel Mata‐Vázquez, María‐Laura Fox, Sonia González de Villambrosía, María‐José Ramírez, Ana García, Valentín García‐Gutiérrez, Amparo Cáceres, María‐Antonia Durán, María‐Alicia Senín, José‐María Raya, José A. González, Beatriz Cuevas, Blanca Xicoy, Jyoti Nangalia, Jesús M. Hernández‐Rivas, Beatriz Bellosillo, Alberto Álvarez‐Larrán, Juan C. Hernández‐Boluda, and Spanish MPN Group (GEMFIN)

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2024
Full Text
View/download PDF

2. PB1962: INFLUENCE OF TRANSCRIPT TYPES IN SUSTAINED DEEP MOLECULAR RESPONSE (SDMR) AND TREATMENT-FREE REMISSION (TFR) IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS TREATED WITH TKI

Author

Silvia Marce Torra, Aleix Méndez, Antonella Luciana Sturla, Miriam Ratia, Anna Angona Figueras, Paula Amat, Francisca Ferrer-Marín, Silvia Escribano, Emilia Scalzulli, Montserrat Cortes Sansa, Esther Plensa, Natalia Estrada, Marta Cabezon Marco, Mireia Morgades, Maria Alicia Senin Magan, Juan Carlos Hernandez-Boluda, Eduardo Anguita, Massimo Breccia, Valentín García-Gutiérrez, Blanca Xicoy Cirici, and Lurdes Zamora

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

3. PB1944: INDIVIDUALS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA SHOW IMPAIRED HUMORAL BUT NORMAL CELLULAR IMMUNE RESPONSES AFTER RECEIVING A COMPLETE VACCINATION SCHEDULE AGAINST SARS-COV-2

Author

Clara Sánchez-Menéndez, Magdalena Corona, Alejandro Zurdo, Alicia Simón-Rueda, Elena Mateos, Mario Manzanares, Javier García-Pérez, Mayte Pérez-Olmeda, Sara Rodríguez-Mora, María Aránzazu Murciano-Antón, Valentín García-Gutiérrez, Mayte Coiras, and Montserrat Torres

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

4. Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia

Author

Alberto Alvarez-Larrán, Beatriz Cuevas, Patricia Velez, Soledad Noya, Gonzalo Caballero-Navarro, Francisca Ferrer-Marín, Sara Carbonell, Manuel Pérez-Encinas, María Teresa Gómez-Casares, Raúl Pérez-López, Elena Magro, Ana Moretó, Irene Pastor-Galán, Anna Angona, María Isabel Mata-Vázquez, Lucía Guerrero-Fernández, José María Guerra, Gonzalo Carreño-Tarragona, Laura Fox, Ilda Murillo, Valentín García-Gutiérrez, Elvira Mora, Ruth Stuckey, Eduardo Arellano-Rodrigo, Juan Carlos Hernández-Boluda, Arturo Pereira, and On behalf of the MPN Spanish Group (GEMFIN)

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

The International Prognostic Score of thrombosis in Essential Thrombocythemia (IPSET-thrombosis) and its revised version have been proposed to guide thrombosis prevention strategies. We evaluated both classifications to prognosticate thrombosis in 1366 contemporary essential thrombocythemia (ET) patients prospectively followed from the Spanish Registry of ET. The cumulative incidence of thrombosis at 10 years, taking death as a competing risk, was 11.4%. The risk of thrombosis was significantly higher in the high-risk IPSET-thrombosis and high-risk revised IPSET-thrombosis, but no differences were observed among the lower risk categories. Patients allocated in high-risk IPSET-thrombosis (subdistribution hazard ratios [SHR], 3.7 [95% confidence interval, CI, 1.6-8.7]) and high-risk revised IPSET-thrombosis (SHR, 3.2 [95% CI, 1.4-7.45]) showed an increased risk of arterial thrombosis, whereas both scoring systems failed to predict venous thrombosis. The incidence rate of thrombosis in intermediate risk revised IPSET-thrombosis (aged >60 years, JAK2-negative, and no history of thrombosis) was very low regardless of the treatment administered (0.9% and 0% per year with and without cytoreduction, respectively). Dynamic application of the revised IPSET-thrombosis showed a low rate of thrombosis when patients without history of prior thrombosis switched to a higher risk category after reaching 60 years of age. In conclusion, IPSET-thrombosis scores are useful for identifying patients at high risk of arterial thrombosis, whereas they fail to predict venous thrombosis. Controlled studies are needed to determine the appropriate treatment of ET patients assigned to the non-high-risk categories.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results